


Accepted Manuscript

Title: PD-1 /PD-L1 checkpoint in hematological malignancies

Authors: O. Annibali, A. Crescenzi, V. Tomarchio, A. Pagano,
A. Bianchi, A. Grifoni, G. Avvisati



PII: S0145-2126(18)30020-1
DOI: <https://doi.org/10.1016/j.leukres.2018.01.014>
Reference: LR 5900

To appear in: *Leukemia Research*

Received date: 27-9-2017
Revised date: 11-1-2018
Accepted date: 23-1-2018

Please cite this article as: Annibali O, Crescenzi A, Tomarchio V, Pagano A, Bianchi A, Grifoni A, Avvisati G. PD-1 /PD-L1 checkpoint in hematological malignancies. *Leukemia Research* <https://doi.org/10.1016/j.leukres.2018.01.014>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

PD-1 /PD-L1 checkpoint in hematological malignancies

Annibali O¹*, Crescenzi A^{*2}, Tomarchio V¹, Pagano A¹, Bianchi A², Grifoni A³ Avvisati G¹

*AO and CA Equally contributed to the work

¹ Unit of Haematology, Stem Cell Transplantation, and ² Unit of Pathology, University Hospital Campus Bio-Medico, Rome, Italy

³ Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, USA

Corresponding author:

Ombretta Annibali, MD, PhD

Assistant Professor

Hematology, Stem cell transplantation

University Campus Bio-Medico

Via Alvaro del Portillo, 21

00128 Roma

Italy Tel: +39-06-225411, Fax: +39-06-225411933 e-mail: o.annibali@unicampus.it

Keywords: PD-1, PD-L1, PD-1/PD-L1 checkpoint, lymphoproliferative disorders, immunotherapy.

Highlights

1. PD-1/PD-L1 axis and its role in immune surveillance in hematological malignancies
2. Targeting the PD-1/PD-L1 pathway to activate anti-tumor immunity
3. Safety, activity, and efficacy of anti-PD-1 antibody in hematological diseases
4. Anti-PD-1 antibody therapy enhances eradication of refractory Hodgkin Lymphoma
5. Anti-PD-1 and hypomethylating agents a new combination for leukemia patients

Abstract

Download English Version:

<https://daneshyari.com/en/article/8453358>

Download Persian Version:

<https://daneshyari.com/article/8453358>

[Daneshyari.com](https://daneshyari.com)